Kristin Abate is CAO at Karyopharm Therapeutics Inc. (KPTI). They have made 11 open-market trades across 1 company since 2025, most recently 2026-10-01.
CIK 0002045943
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 11 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KPTI | 23,404 | $9K |
Shares reported on the most recent Form 4, priced at the 2026-10-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KPTI | SELL | 2026-10-01 | 2026-10-02 | $1.19 | $450 | -59.3% | — | — |
| KPTI | SELL | 2026-09-01 | 2026-09-02 | $2.02 | $38 | -13.0% | -54.7% | — |
| KPTI | SELL | 2026-05-14 | 2026-05-15 | $9.50 | $504 | +17.1% | +23.6% | -74.5% |
| KPTI | SELL | 2026-03-02 | 2026-03-03 | $9.41 | $5K | -13.9% | -35.4% | +7.7% |
| KPTI | SELL | 2026-01-28 | 2026-01-29 | $7.03 | $352 | -1.0% | +44.1% | +26.4% |
| KPTI | SELL | 2026-01-21 | 2026-01-22 | $5.96 | $2K | -2.2% | +49.7% | +42.5% |
| KPTI | SELL | 2025-10-01 | 2025-10-03 | $6.30 | $2K | -6.7% | -4.9% | +12.7% |
| KPTI | SELL | 2025-09-15 | 2025-09-16 | $6.43 | $148 | +5.3% | -3.1% | +7.9% |
| KPTI | SELL | 2025-09-03 | 2025-09-04 | $6.78 | $81 | -6.7% | -8.2% | -18.6% |
| KPTI | SELL | 2025-07-22 | 2025-07-23 | $4.00 | $952 | -14.5% | +34.0% | +36.8% |
| KPTI | SELL | 2025-03-04 | 2025-03-06 | $6.29 | $4K | -6.6% | -35.3% | -30.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.